Deucravacitinib in Psoriasis - 5 Year Outcomes Save

BMS released new five-year results from the POETYK PSO long-term extension (LTE) trial of deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. The data was presented by Dr. Marc Lebwohl at the Winter Clinical Dermatology Conference in Hawaii February 14-19, 2025.

The efficacy analysis included 513 patients who received continuous treatment from Day 1 in the pivotal POETYK PSO-1 and POETYK PSO-2 trials and transitioned to the POETYK PSO-LTE trial. The safety analysis included 1,519 patients who received at least one dose during the trials. 

With over 5,000 patient-years of observation in the trial, there were no new safety signals identified and efficacy was maintained from Year 1 to Year 5. Clinical responses were assessed by Psoriasis Area and Severity Index (PASI) 75, PASI 90 and static Physician’s Global Assessment (sPGA) 0/1 (clear/almost clear).

Sustained clinical efficacy on deucravacitinib  was demonstrated: 

• PASI 75 (72.1%, Year 1; 67.3%, Year 5)
• PASI 90 (45.9%, Year 1; 46.3%, Year 5) 
• sPGA 0/1 (57.5%, Year 1; 52.6%, Year 5)

Deucravacitinib (Sotyktu) is approved for the treatment of adults with moderate-to-severe plaque psoriasis.